Eleopra, R.; Rinaldo, S.; Lettieri, C.; Santamato, A.; Bortolotti, P.; Lentino, C.; Tamborino, C.; Causero, A.; Devigili, G.
AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study. Toxins 2018, 10, 448.
https://doi.org/10.3390/toxins10110448
AMA Style
Eleopra R, Rinaldo S, Lettieri C, Santamato A, Bortolotti P, Lentino C, Tamborino C, Causero A, Devigili G.
AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study. Toxins. 2018; 10(11):448.
https://doi.org/10.3390/toxins10110448
Chicago/Turabian Style
Eleopra, Roberto, Sara Rinaldo, Christian Lettieri, Andrea Santamato, Paolo Bortolotti, Carmelo Lentino, Carmine Tamborino, Araldo Causero, and Grazia Devigili.
2018. "AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study" Toxins 10, no. 11: 448.
https://doi.org/10.3390/toxins10110448
APA Style
Eleopra, R., Rinaldo, S., Lettieri, C., Santamato, A., Bortolotti, P., Lentino, C., Tamborino, C., Causero, A., & Devigili, G.
(2018). AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study. Toxins, 10(11), 448.
https://doi.org/10.3390/toxins10110448